Merck, Inc.
🇵🇭Philippines
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
Phase 4
Terminated
- Conditions
- Hepatitis C, ChronicInsulin Resistance
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 59
- Registration Number
- NCT00493805
A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 218
- Registration Number
- NCT00491764
A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)
Phase 3
Completed
- Conditions
- Hepatitis B Infection
- Interventions
- Biological: V232 Current Process Hepatitis B Vaccine
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 860
- Registration Number
- NCT00489099
Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
Phase 2
Terminated
- Conditions
- Blood DiseaseMyelodysplastic SyndromesBone Marrow Disease
- Interventions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00486720
Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)
Phase 3
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: ER niacin/laropiprant
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 796
- Registration Number
- NCT00485758
Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)
Phase 3
Completed
- Conditions
- Migraines
- Interventions
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1935
- Registration Number
- NCT00483704
A Study of MK0359 in Patients With Chronic Asthma (0359-013)
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 56
- Registration Number
- NCT00482898
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
Phase 2
Completed
- Conditions
- Paranoid SchizophreniaSchizophrenia
- Interventions
- Drug: MK0557
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00482430
Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)
Phase 2
Completed
- Conditions
- Obesity
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00482638
Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00482599
© Copyright 2025. All Rights Reserved by MedPath